New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage

Clin Genet. 2023 Mar;103(3):371-376. doi: 10.1111/cge.14266. Epub 2022 Nov 22.

Abstract

The update of the review on the effects of switching from agalsidase beta to alfa showed, in comparison to the previous review, an increased number of clinical events, a significant loss of renal function, and an increase in lyso Gb-3 levels, underscoring the importance of dose in the treatment of FD.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enzyme Replacement Therapy
  • Fabry Disease* / drug therapy
  • Fabry Disease* / genetics
  • Humans
  • Isoenzymes / genetics
  • Isoenzymes / therapeutic use
  • Treatment Outcome
  • alpha-Galactosidase / genetics
  • alpha-Galactosidase / therapeutic use

Substances

  • agalsidase beta
  • alpha-Galactosidase
  • Isoenzymes